LB Pharmaceuticals Presents New Analysis from the Phase 2 NOVA-1 Trial Highlighting LB-102’s Potential Impact on Cognitive Performance at the 2026 Annual Congress of the Schizophrenia International Research Society (SIRS)
TM
tristan manalac
via Biospace
Updated 1h ago
Source Verification
Corroboration Score: 1This story was independently reported by 1 sources. Click any source to read the original article.
Comments
0 commentsBe respectful and constructive.
Loading comments...
Previous
Sophie Turner back injury shuts down filming on Lara Croft reboot
Next
Managed wetlands a culinary hot spot for SF bay fish, but they need delivery options
Related Articles
PoliticsDonald Trump Tears into 'Dumb' Supreme Court Justices
Giulia Carbonaro-2h ago-1 sources
PoliticsU.S. will let Russian oil tanker reach Cuba, breaking Trump’s effective fuel blockade
Anthony Faiola / The Washington Post,Karen Deyoung,Samantha Schmidt-10h ago-2 sources
PoliticsThousands form 'No Kings in the USA' human banner in Chandler
The Arizona Republic-13h ago-1 sources